Exporting cannabis from Canada to Israel requires compliance with two distinct regulatory regimes: Health Canada's export authorisation process under the Cannabis Act, and Israel's IMC-GMP and GACP standards administered by the Israel Medical Cannabis Agency. Canadian Licensed Producers that meet both frameworks have access to one of the most established medical cannabis markets outside the EU, where patient volumes and reimbursement rates support consistent B2B demand.
Israel has operated a regulated medical cannabis programme since 2011 and now ranks among the world's more sophisticated import markets. Patients access cannabis through licensed pharmacies, which source exclusively from approved suppliers. For a Canadian LP, that means your compliance documentation is not just a checkbox. It is your market entry credential.
This guide covers the Israeli regulatory framework, the five compliance steps a Canadian LP must complete before a first shipment, and what pharmaceutical distributors in Israel actually look for when evaluating a new supply partner.
Why Israel is a priority market for Canadian cannabis LPs
Israel's medical cannabis programme has been operating longer than most comparable markets and has a well-developed pharmacy distribution channel. Patients receive cannabis through licensed pharmacies on physician prescription, and pharmacies source from importers that hold standing approval from the Israel Medical Cannabis Agency. The result is a structured B2B supply relationship, not a spot market.
Volumes have grown steadily as Israel expanded prescription access and increased approved patient numbers. The country also has an active domestic cultivation sector, but importers continue to source internationally for specific formats, genetics, and potency profiles that local production does not fully cover. Premium indoor-grown large-bud flower with documented cannabinoid profiles sits in that gap.
For Canadian LPs with EU-GMP alignment already in place, the Israeli compliance requirements are a manageable extension. The documentation logic is similar: the Israeli system values the same quality pillars that German importers do. If you have built a compliant export programme for Europe, adapting it to Israel is largely a documentation exercise, not a facility rebuild.
Understanding the Israeli regulatory framework for imported cannabis
Two Israeli standards govern medical cannabis imports: IMC-GMP (Israeli Medical Cannabis Good Manufacturing Practice) and IMC-GAP (Israeli Medical Cannabis Good Agricultural Practice). Both are administered by the Israel Medical Cannabis Agency, which sits within the Israeli Ministry of Health.
IMC-GMP requirements
IMC-GMP covers the production and quality management requirements that an exporting LP must meet. Canadian Health Canada Good Production Practices (GPP) overlap substantially with IMC-GMP in the areas of batch documentation, environmental monitoring, and product testing. However, Israeli importers typically require a formal IMC-GMP equivalency assessment before finalising a supply agreement. An approved inspection body reviews the LP's SOPs, batch records, and facility controls against the IMC-GMP standard and issues a finding. This assessment takes time and should be initiated early in the partnership development process.
IMC-GAP and GACP
GACP (Good Agricultural and Collection Practices) is a European cultivation standard that Israel's IMC-GAP framework references. For indoor cannabis producers, GACP compliance translates to documented environmental controls, input traceability, integrated pest management records, and harvest-to-packaging chain-of-custody. Canadian LPs that already maintain this level of grow documentation are well-positioned to satisfy IMC-GAP requirements without substantial additional work.
Per-shipment narcotic import permit
Unlike Germany's annual narcotic import permit, Israel issues permits on a per-shipment basis. The Israeli importer applies to the Israel Medical Cannabis Agency for each consignment. The permit application references the supplier, the specific batch, the quantity, and the ISO/IEC 17025-accredited certificate of analysis covering that batch. Canadian LPs should plan for this cadence in their logistics schedule: your importer needs your COA and batch-specific documentation at least several weeks before planned ship date to allow permit processing. For a deeper look at what goes into a compliant COA package, see our guide to reading a cannabis certificate of analysis.
Phytosanitary requirements
Cannabis exported to Israel requires a phytosanitary certificate from the Canadian Food Inspection Agency (CFIA), confirming the goods meet Israel's plant health import conditions. CFIA issues these on application from the LP, and the processing window should be built into the pre-shipment timeline. Missing or late phytosanitary certificates are a common cause of customs holds on cannabis consignments.
The Canadian LP 5-step Israel compliance path
The following sequence outlines the compliance steps a Canadian LP must complete before a first shipment to Israel. This is the structure most importers and compliance consultants follow when onboarding a new Canadian supplier. Treat it as a checklist, not a guarantee: timelines vary depending on the importer's standing with the Israel Medical Cannabis Agency and the LP's documentation readiness.
Step 1: Confirm export authorisation under the Cannabis Act
The first requirement is a valid export authorisation issued by Health Canada under the Cannabis Act. Export authorisations for medical cannabis are country-specific and cover a defined period. If you hold an existing authorisation for another market, confirm it covers Israel or apply for a new one. Health Canada's processing time for export authorisation applications is typically several weeks; plan accordingly.
Step 2: Identify an Israeli importer with Agency standing
You cannot ship directly to a pharmacy. You need an Israeli importer that already holds standing approval from the Israel Medical Cannabis Agency to import cannabis. Finding the right importer is a business development task as much as a compliance task. Israeli pharmaceutical distributors vary by market segment, pharmacy network, and format preference. A Canadian LP with premium indoor large-bud flower should approach importers whose pharmacy network serves the patient population that prefers that format.
Step 3: Complete the IMC-GMP equivalency assessment
Your importer will initiate the supplier approval process by submitting your facility's documentation package to the Israel Medical Cannabis Agency or to an approved inspection body. Prepare: your Health Canada licence, current SOPs, batch records for recent production runs, your ISO/IEC 17025 testing programme documentation, and any EU-GMP or GACP audit reports you hold. The more complete your documentation package, the faster the assessment proceeds. For background on EU-GMP and how Canadian LPs satisfy equivalency assessments, see EU-GMP certification for Canadian cannabis LPs.
Step 4: Prepare per-shipment documentation
Once approved as a supplier, each shipment requires a batch-specific documentation package:
- Health Canada export permit for that consignment
- ISO/IEC 17025-accredited certificate of analysis for the specific batch
- Phytosanitary certificate from CFIA
- Commercial invoice and packing list
- Any batch-specific GACP or cultivation records the importer requires
Your importer submits the per-shipment narcotic import permit application to the Israel Medical Cannabis Agency using this package. Build at least three to four weeks of lead time into your logistics schedule for permit processing.
Step 5: Coordinate customs clearance and cold-chain delivery
Cannabis enters Israel through designated customs points. Your freight forwarder must have experience with narcotics-classified goods and must carry copies of all permits for the consignment. Delivery to the importer's licensed storage facility completes the shipment. At that point, the importer takes custody and manages distribution into the pharmacy channel.
What Israeli pharmaceutical distributors evaluate in a Canadian LP
Israeli pharmaceutical distributors are experienced cannabis buyers. They have worked with multiple international suppliers and know what good documentation looks like. Before committing to a supply agreement, a distributor will typically evaluate a Canadian LP on the following:
- IMC-GMP status or readiness: a prior audit report or evidence of GMP equivalency reduces their onboarding risk significantly
- ISO/IEC 17025 testing credentials: batch COAs from an accredited third-party lab are non-negotiable; in-house testing data alone does not satisfy Israeli requirements
- Cannabinoid and terpene consistency: distributors want batch-to-batch stability, not variance; presenting COA data across multiple recent batches demonstrates this
- Format and genetics: large-bud indoor flower with documented strain genetics commands a premium in the Israeli medical channel; unnamed or inconsistently described genetics raise procurement questions
- Supply reliability: distributors need to know you can commit to a supply schedule; irregular production or export permit gaps are deal-breakers for importers with pharmacy commitments
- Communication responsiveness: Israeli importers work across time zones with multiple international suppliers; Canadian LPs that respond promptly in English with clear documentation move faster through onboarding
AlphaLeaf operates as a Montreal-based Licensed Producer of premium indoor-grown, hand-trimmed cannabis flower with export authorisation under the Cannabis Act. We maintain ISO/IEC 17025-certified batch testing, full traceability records, and the GACP-aligned cultivation documentation that Israeli pharmaceutical distributors require. Our compliance records and refined genetics programme support the IMC-GMP equivalency process that makes a first Israeli shipment achievable.
If you are an Israeli importer evaluating Canadian supply partners, we are available to provide our documentation package and discuss the fit with your pharmacy network. Contact us to start the conversation.
Frequently Asked Questions
Can a Canadian Licensed Producer export cannabis directly to Israel?
Yes. Canadian Licensed Producers holding a valid export authorisation under the Cannabis Act can ship to Israeli importers that hold a narcotic import permit issued by the Israel Medical Cannabis Agency. Both permits must be in place before any shipment crosses the border.
What is IMC-GMP and does a Canadian LP need it to export to Israel?
IMC-GMP is the Israeli Medical Cannabis Good Manufacturing Practice standard. Israeli importers are required to source from GMP-certified facilities. Canadian LPs certified under Health Canada's Good Production Practices framework can submit documentation for IMC-GMP equivalency review, though formal certification from an approved inspection body is typically required before first shipment.
What is a phytosanitary certificate and is it required for cannabis exports to Israel?
A phytosanitary certificate is an official document issued by a national plant protection authority confirming that plant-based goods meet the importing country's phytosanitary requirements. For cannabis exports to Israel, a phytosanitary certificate from the CFIA is typically required alongside the standard export permit package.
How long does the Israeli narcotic import permit process take?
The narcotic import permit for cannabis in Israel is issued on a per-shipment basis. Established importers with a pre-approved supplier relationship typically see permits within two to four weeks of application. New supplier onboarding takes longer because the importer must first submit the Canadian LP's compliance documentation for Agency review.
Does GACP certification help a Canadian LP access the Israeli market?
Yes. The Israel Medical Cannabis Agency's IMC-GAP standard references GACP principles for cultivation. Canadian LPs that can demonstrate GACP-aligned growing practices, with documented environmental controls, input traceability, and harvest protocols, strengthen their IMC-GMP equivalency submissions and their standing with Israeli pharmaceutical distributors.
